Bicycle Therapeutics (BCYC) Earnings Analysis
Bicycle Therapeutics (BCYC) next reports earnings on 2026-08-14, consensus EPS -0.564 USD. Last quarter (2026-04-30) it missed with EPS -0.87 USD vs -0.52 USD est (-67.3%). It has beaten estimates in 3/6 recent quarters (50%). Trailing P/E -1.34.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does BCYC next report earnings?
| Next earnings date | 2026-08-14 |
|---|---|
| Consensus EPS estimate | -0.564 USD |
| Revenue estimate | 0.00B |
BCYC earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-30 | -0.87 USD | -0.52 USD | -67.3% | Miss |
| 2026-03-17 | -0.29 USD | -0.93716 USD | +69.1% | Beat |
| 2025-10-30 | -0.85 USD | -1.09 USD | +22% | Beat |
| 2025-08-08 | -1.14 USD | -0.95 USD | -20% | Miss |
| 2025-05-01 | -0.88 USD | -0.86 USD | -2.3% | Miss |
| 2024-10-31 | -0.74 USD | -0.78 USD | +5.1% | Beat |
Beat rate: 3/6 (50%) over reported quarters with consensus data.
BCYC valuation and analyst view
| Trailing P/E | -1.34 |
|---|---|
| Trailing EPS | -3.14323 USD |
| Price / book | 0.53 |
| Dividend yield | 0.00% |
| Market cap | 0.29B |
| Analyst consensus | Buy (17 buy / 4 hold / 0 sell) |
| Avg price target | 12 USD |
Related research pages
Frequently asked questions
When is Bicycle Therapeutics (BCYC)'s next earnings date?
Bicycle Therapeutics is next scheduled to report on 2026-08-14, with a consensus EPS estimate of -0.564 USD and revenue estimate of 0.00B.
Did BCYC beat earnings last quarter?
In its 2026-04-30 report, BCYC posted EPS of -0.87 USD versus a -0.52 USD estimate — a miss of 67.3%.
What is BCYC's earnings track record?
Over the last 6 reported quarters with consensus data, BCYC beat estimates 3 times (50%).
What is BCYC's current P/E ratio and EPS?
BCYC trades at a trailing P/E of -1.34 on trailing EPS of -3.1432274663815183 USD.
What do analysts rate BCYC?
Analyst consensus is "Buy" across 21 ratings (0 strong buy, 17 buy, 4 hold, 0 sell, 0 strong sell). Average 12-month price target: 12 USD.